Newsroom | 49460 results

INCHEON, Corea--(BUSINESS WIRE)--Samsung Epis Holdings (KRX: 0126Z0) ha presentato oggi i progressi e gli aggiornamenti aziendali in occasione della 44esima edizione della J.P. Morgan Healthcare Conference. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido....

BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, announces the planned start of a phase III study assessing the efficacy and safety of Lebrikizumab (Ebglyss®, currently approved for the treatment of moderate-to-severe atopic dermatitis) in patients with nummular eczema. This study will be initiated in the first half of 2026 and is aligned with Almirall’s ambition of leadership in medical dermatology and is part of the ong...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Epis Holdings shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference....

EVANSTON, Ill.--(BUSINESS WIRE)--Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced the appointment of Venkat R. Krishnamurthy, Ph.D., as Chief Scientific Officer. Dr. Krishnamurthy is an accomplished scientific and executive leader with more than 15 years of experience developing RNA therapeutics, bringing deep expertise in oligonucleotide chemistry, drug delivery, and advancing genetic medicine programs from discovery through c...

MORRISVILLE, Caroline du Nord--(BUSINESS WIRE)--WEP Clinical (WEP), une organisation de recherche sous contrat (ontract research organization, CRO) à services complets, vient d’annoncer l’acquisition de Siron Clinical (Siron), une CRO européenne basée aux Pays-Bas, spécialisée dans les opérations cliniques flexibles et de haute qualité pour les entreprises de biotechnologie. Cette acquisition permet à WEP d’élargir sa présence mondiale et de renforcer sa capacité à fournir des solutions complèt...

米ノースカロライナ州モリスビル--(BUSINESS WIRE)--（ビジネスワイヤ） -- フルサービスのCRO（開発業務受託機関）であるWEPクリニカル（WEP）は、バイオテクノロジー企業向けに柔軟かつ高品質な臨床オペレーションを専門とするオランダに拠点を置く欧州CROシロン・クリニカル（シロン）の買収を発表しました。これにより、WEPのグローバル展開が拡大するとともに、複雑、希少、専門性の高い治療領域におけるエンドツーエンドの第I相～IV相臨床試験ソリューションの提供能力が強化されます。 2000年に設立されたシロンは、オランダに本社を置き、ベルギーとドイツにもオフィスを構え、ヨーロッパと中東に臨床研究の専門家を擁しています。同社は、プロジェクト管理、臨床モニタリング、品質保証、薬事申請などの臨床オペレーションを専門としています。シロンは120件以上の研究を支援しており、希少疾患、小児研究、医療機器試験において優れた実績を誇ります。 WEPの創業者兼CEO、ジャスウィンダー・ケラのコメント： 「今回の買収は、当社のCROサービスの進化における重要なマイルストーンとなります。WE...

MORRISVILLE, N.C.--(BUSINESS WIRE)--WEP Clinical (WEP), una organización de investigación por contrato (CRO) de servicio completo, anunció la incorporación de Siron Clinical (Siron), una CRO europea con sede en los Países Bajos especializada en operaciones clínicas flexibles y de alta calidad para empresas de biotecnología. Esta adquisición amplía la presencia global de WEP y fortalece su capacidad para ofrecer soluciones integrales para ensayos clínicos de Fase I a IV en áreas terapéuticas com...

MORRISVILLE, N.C.--(BUSINESS WIRE)--WEP Clinical (WEP), un'organizzazione di ricerca a contratto (CRO) che offre servizi completi, annuncia l'acquisizione di Siron Clinical (Siron), una CRO europea con sede nei Paesi Bassi, specializzata in attività cliniche flessibili e ad alta qualità per aziende biotecnologiche. L'acquisizione amplia la presenza globale di WEP e rafforza la sua capacità di realizzare soluzioni complete per studi clinici di fase I-IV in aree terapeutiche complesse, rare e spe...

DUBLIN--(BUSINESS WIRE)--The "Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions" has been added to ResearchAndMarkets.com's offering. The peptide therapeutics market is poised for significant growth, projected to escalate from USD 84.2 billion in 2023 to USD 162.4 billion by 2035, marking a CAGR of 6.8%. These therapeutics, built from polypeptides, are increasingl...

PLYMOUTH, Minn.--(BUSINESS WIRE)--VizMark Secures FDA 510k clearance for VM1 Visual Tumor Marker, Advancing Precision in Breast Cancer Imaging...